|
TP1736L |
Fibrinogen-Binding Peptide fb-acetate
|
Fibrinogen-Binding Peptide （137235-80-4 fb-acetate) |
Others
|
|
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits ... |
|
TP1736 |
Fibrinogen-Binding Peptide
|
|
|
|
Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen, a soluble plasma protein, is a cofactor in pl... |
|
TP1778 |
Fibrinogen Binding Inhibitor Peptide
|
|
|
|
Fibrinogen Binding Inhibitor Peptide, a synthetic dodecapeptide, represents the specific platelet receptor recognition site of the human fibrinogen g-chain (residues 400-411). |
|
TP1458L |
Arg-Gly-Glu-Ser acetate(93674-97-6 free base)
|
|
Others
|
|
Arg-Gly-Glu-Ser acetate is a RGD related peptide that is a control for the RGDS activity of fibrinogen binding to activated platelets. |
|
T26629 |
Angstrom6
|
A-6,A 6 peptide,A6,A 6,A6 peptide,A-6 peptide |
PAI-1
|
|
Angstrom6 (A-6 peptide) is an 8 amino acid peptide derived from single chain urokinase fibrinogen activator (scuPA) that interferes with the uPA/uPAR cascade and abrogates the downstream effects.Angstrom6 has antitumor a... |
|
TP1458 |
Arg-Gly-Glu-Ser
|
|
|
|
Arg-Gly-Glu-Ser is a RGD related peptide that is a control for the RGDS activity of fibrinogen binding to activated platelets. |
|
T81985 |
K-Casein (106-116),bovine
|
|
|
|
K-Casein (106-116), bovine, is a peptide that impedes platelet aggregation and fibrinogen binding, significantly contributing to the pathophysiology of atherosclerosis [1]. |
|
T78001 |
Arg-Gly-Glu-Ser TFA
|
|
|
|
Arg-Gly-Glu-Ser TFA, an RGD-related peptide, serves as a control for evaluating the inhibitory activity of RGDS on fibrinogen binding to activated platelets. |
